J
James L. Kirkland
Researcher at Mayo Clinic
Publications - 322
Citations - 33834
James L. Kirkland is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Senescence & Adipose tissue. The author has an hindex of 76, co-authored 280 publications receiving 23328 citations. Previous affiliations of James L. Kirkland include Buck Institute for Research on Aging & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Frailty in CKD and Transplantation.
Elizabeth C. Lorenz,Cassie C. Kennedy,Andrew D. Rule,Nathan K. LeBrasseur,James L. Kirkland,La Tonya J. Hickson +5 more
TL;DR: Current interventions to reduce frailty are promising, but additional investigations are needed to determine whether optimizing frailty measures improves renal and overall health outcomes.
Journal ArticleDOI
Oleate-induced formation of fat cells with impaired insulin sensitivity.
TL;DR: It is suggested that this unique fat cell phenotype might be a mimetic of what can happen to fat cells formed in vivo under the influence of circulating FA andmight be a useful model for in vitro studies of obesity-related insulin resistance in adipocytes.
Journal ArticleDOI
COVID-19 and cellular senescence
Clemens A. Schmitt,Tamara Tchkonia,Laura J. Niedernhofer,Paul D. Robbins,James L. Kirkland,Soyoung Lee +5 more
TL;DR: In this article , the authors point out that cellular senescence, an ageing-related switch in cellular state, is a critical regulator of SARS-CoV-2-evoked hyperinflammation.
Journal ArticleDOI
Deleted in Breast Cancer 1 regulates cellular senescence during obesity.
Carlos Escande,Carlos Escande,Veronica Nin,Tamar Pirtskhalava,Claudia C.S. Chini,Maria Thereza Barbosa,Angela Mathison,Raul Urrutia,Tamar Tchkonia,James L. Kirkland,Eduardo N. Chini +10 more
TL;DR: It is proposed that by regulating HDAC3 activity during cellular damage, DBC1 participates in the fate decision that leads to the establishment of cellular senescence and consequently to inflammation and tissue dysfunction during obesity.
Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): A Pilot Clinical Trial
Mitzi M. Gonzales,Valentina R. Garbarino,E. Marques Zilli,R. C. Petersen,James L. Kirkland,Tamar Tchkonia,Nicolas Musi,Sudha Seshadri,Sudha Seshadri,Suzanne Craft,Miranda E. Orr +10 more
TL;DR: In this paper, an open-label clinical trial pilots an intermittent senolytic combination therapy of dasatinib plus quercetin in five older adults with early stage Alzheimer's disease.